Rigel names Alison Hannah CMO, replacing Lisa Rojkjaer who departed June 25

Rigel Pharmaceuticals replaced its Chief Medical Officer in a transition that raises questions about the circumstances of the departure. Lisa Rojkjaer separated from the company effective June 25, 2026, with the 8-K providing no explanation for why she left or whether the separation was voluntary.

The lack of disclosure around a C-suite medical officer's exit is unusual and leaves investors without visibility into whether this reflects strategic differences, performance issues, or other concerns. The company moved quickly to fill the role, appointing Alison Hannah as Executive Vice President and Chief Medical Officer effective July 1, 2026.

Hannah had served on Rigel's board since May 2021 and resigned that position to take the executive role. She brings substantial drug development credentials, including a prior CMO role at CytomX Therapeutics and senior medical leadership at SUGEN. The board-to-executive transition suggests the company had an internal succession candidate ready, though the abrupt timing and silence on Rojkjaer's departure warrant attention from shareholders tracking clinical execution and leadership stability.